• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改善偏头痛亚型分类:基于美国偏头痛患病率和预防研究(AMPP)中因子混合模型的实证方法。

Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the American Migraine Prevalence and Prevention (AMPP) Study.

机构信息

Albert Einstein College of Medicine, Bronx, NY, USA; Montefiore Medical Center, Bronx, NY, USA.

出版信息

Headache. 2014 May;54(5):830-49. doi: 10.1111/head.12332. Epub 2014 Apr 17.

DOI:10.1111/head.12332
PMID:24527745
Abstract

OBJECTIVES

Refine the classification of migraine subtypes by applying factor mixture models (FMM) to a large population sample of people with headache.

BACKGROUND

Current classification of primary headache disorders is symptom-based and uses somewhat arbitrary boundaries developed by expert consensus. Symptom profiles and headache frequency are used to distinguish among probable migraine (PM), episodic migraine (EM), high-frequency episodic migraine (HFEM), and chronic migraine (CM). Herein, we used statistical approaches to parse the heterogeneity in the broad group of persons with migraine and test the hypothesis that the groups that emerge differ in prognosis.

METHODS

The American Migraine Prevalence and Prevention study mailed surveys to a sample of 120,000 US households selected to represent the US population in 2004. Follow-up surveys were sent to a random sample of 24,000 respondents with "severe headache" on an annual basis from 2005 to 2009. People meeting International Classification of Headache Disorders, Second Edition, criteria for migraine were classified as EM (<15 headache days/month) and CM (≥15 headache days/month) based on modified Silberstein-Lipton criteria. The EM group was subdivided into HFEM (10 to 14 headache days/month) and low-frequency episodic migraine (LFEM; <10 headache days/month). Factor mixture models (FMM) identified 5 subgroups of migraine (taxa) using data from the 2005 survey on the severity of migraine symptoms, average migraine pain intensity, headache-related disability, cutaneous allodynia and depression, as well as monthly headache and migraine frequency as determinants of class membership. We assessed the validity of these taxa by examining the distribution of clinical diagnoses at cross-section and the rate of CM onset within these groups.

RESULTS

Data from the 2005 American Migraine Prevalence and Prevention survey were used for the FMM and data from the 2006-2009 surveys were used to assess prognosis of groups defined based on FMM. In total, 12,860 participants were eligible for classification analysis, including 10,162 with LFEM and 601 with HFEM, 1302 with probable migraine, and 795 with CM. Of these, 3152 (24.5%), 1076 (8.4%), 3896 (30.3%), 2251 (17.5%), and 2485 (19.3%) were assigned to Taxons 1, 2, 3, 4, and 5, respectively. Overall, there was a strong association between taxon assignment and clinical diagnosis. As the most prevalent disorder in the sample, EM was the largest contributor to each of the 5 taxa, constituting more than 80% of each group other than Taxon 2. Taxon 2 was enriched with the most severe spectrum of migraine including the highest concentrations of CM (28.4%) and HFEM (22.6%), whereas Taxon 5 represented the least severe end of the migraine spectrum including the lowest concentrations of CM (0%) and HFEM (0.08%). Validity of taxon assignment was tested by the ability of taxon membership to predict clinical course. For Taxon 2, 22% of those free of CM at baseline developed it. For Taxon 5, less than 2% of CM-free Taxon 5 members developed it.

CONCLUSION

Statistically based classification using FMM extends traditional clinical syndrome-based diagnosis. FMM can serve as an important tool to parse phenotypic heterogeneity and identify natural migraine subgroups. This approach may improve our ability to diagnosis migraine, to select initial therapy, to predict prognosis, and to discover biomarkers and genes.

摘要

目的

通过因子混合模型(FMM)对大量头痛人群样本进行分类,以完善偏头痛亚型的分类。

背景

原发性头痛障碍的现行分类是基于症状的,并使用专家共识制定的一些任意边界。症状谱和头痛频率用于区分可能的偏头痛(PM)、发作性偏头痛(EM)、高频发作性偏头痛(HFEM)和慢性偏头痛(CM)。在此,我们使用统计方法来分析广泛的偏头痛人群的异质性,并检验以下假设:即出现的组在预后方面存在差异。

方法

美国偏头痛患病率和预防研究向 2004 年随机抽取的代表美国人口的 12 万户美国家庭邮寄了调查问卷。从 2005 年开始,每年向 24000 名“严重头痛”的随机样本发送年度调查问卷。根据改良的 Silberstein-Lipton 标准,符合国际头痛疾病分类,第二版偏头痛标准的患者被归类为 EM(每月头痛天数<15 天)和 CM(每月头痛天数≥15 天)。EM 组进一步分为 HFEM(每月头痛天数 10-14 天)和 LFEM(每月头痛天数<10 天)。因子混合模型(FMM)使用 2005 年关于偏头痛症状严重程度、平均偏头痛疼痛强度、头痛相关残疾、皮肤感觉过敏和抑郁以及每月头痛和偏头痛频率作为分类成员决定因素的调查数据,确定了偏头痛的 5 个亚群(分类单元)。我们通过检查横断面的临床诊断分布和这些组内 CM 发病的速度来评估这些分类单元的有效性。

结果

使用 2005 年美国偏头痛患病率和预防调查的数据进行 FMM 分析,使用 2006-2009 年调查的数据来评估基于 FMM 定义的组的预后。共有 12860 名参与者符合分类分析条件,包括 LFEM 组 10162 名,HFEM 组 601 名,可能偏头痛组 1302 名,CM 组 795 名。其中,3152(24.5%)、1076(8.4%)、3896(30.3%)、2251(17.5%)和 2485(19.3%)分别被分配到分类单元 1、2、3、4 和 5。总体而言,分类单元的分配与临床诊断之间存在很强的关联。作为样本中最常见的疾病,EM 是每个分类单元的最大贡献者,除分类单元 2 外,每个组的 EM 都占比超过 80%。分类单元 2 包含偏头痛最严重的谱,包括 CM(28.4%)和 HFEM(22.6%)的最高浓度,而分类单元 5 则代表偏头痛谱的最轻微端,包括 CM(0%)和 HFEM(0.08%)的最低浓度。分类单元的分配有效性通过分类单元成员预测临床病程的能力进行测试。对于分类单元 2,基线时无 CM 的患者中有 22%发展为 CM。对于分类单元 5,无 CM 的分类单元 5 成员中不到 2%发展为 CM。

结论

基于 FMM 的统计分类方法扩展了传统的基于临床综合征的诊断。FMM 可以作为一种重要的工具,用于分析表型异质性和识别自然偏头痛亚群。这种方法可以提高我们诊断偏头痛、选择初始治疗、预测预后以及发现生物标志物和基因的能力。

相似文献

1
Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the American Migraine Prevalence and Prevention (AMPP) Study.改善偏头痛亚型分类:基于美国偏头痛患病率和预防研究(AMPP)中因子混合模型的实证方法。
Headache. 2014 May;54(5):830-49. doi: 10.1111/head.12332. Epub 2014 Apr 17.
2
Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study.慢性偏头痛的患病率、残疾程度和社会人口学因素:来自美国偏头痛患病率和预防研究的结果。
Headache. 2012 Nov-Dec;52(10):1456-70. doi: 10.1111/j.1526-4610.2012.02223.x. Epub 2012 Jul 25.
3
Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.慢性和阵发性偏头痛的头痛影响:来自美国偏头痛患病率和预防研究的结果。
Headache. 2012 Jan;52(1):3-17. doi: 10.1111/j.1526-4610.2011.02046.x. Epub 2011 Nov 22.
4
Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.在曲坦类药物治疗偏头痛方案中添加其他急性药物以及观察到的与头痛相关的残疾变化:美国偏头痛患病率与预防(AMPP)研究的结果
Headache. 2015 Jun;55(6):825-39. doi: 10.1111/head.12556. Epub 2015 Apr 17.
5
Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.发作性偏头痛患者未满足的治疗需求调查:美国偏头痛患病率和预防研究(AMPP 研究)结果。
Headache. 2013 Sep;53(8):1300-11. doi: 10.1111/head.12154. Epub 2013 Jul 23.
6
Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.发作性和慢性偏头痛的急性治疗优化:美国偏头痛患病率与预防(AMPP)研究结果
Headache. 2015 Apr;55(4):502-18. doi: 10.1111/head.12553.
7
Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results.持续性频繁恶心与慢性偏头痛的进展相关:AMPP研究结果。
Headache. 2015 Jan;55(1):76-87. doi: 10.1111/head.12450. Epub 2014 Sep 24.
8
Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study.偏头痛、可能的偏头痛和其他严重头痛的患病率、症状和相关特征的性别差异:美国偏头痛患病率和预防(AMPP)研究的结果。
Headache. 2013 Sep;53(8):1278-99. doi: 10.1111/head.12150. Epub 2013 Jun 28.
9
Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study.偏头痛患者的人口统计学特征、头痛特点及合并症概况与头痛频率的关系:美国偏头痛患病率与预防(AMPP)研究结果
Headache. 2020 Oct 14. doi: 10.1111/head.13966.
10
A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability.慢性偏头痛流行病学与转归(CaMEO)研究和美国偏头痛患病率与预防(AMPP)研究的比较:人口统计学和头痛相关残疾情况
Headache. 2016 Sep;56(8):1280-9. doi: 10.1111/head.12878. Epub 2016 Jun 28.

引用本文的文献

1
Investigation of Sensory and Neuropsychological Parameters in Migraine Sufferers: A Cross-Sectional Study with Negative Findings.偏头痛患者的感觉和神经心理学参数研究:一项结果为阴性的横断面研究。
Neurol Ther. 2025 Sep 6. doi: 10.1007/s40120-025-00824-9.
2
Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation.现实生活实践中的药物使用不足:加卡尼单抗对东南亚一个中等收入国家实现极低频率发作性偏头痛的影响。
J Headache Pain. 2025 Jan 16;26(1):13. doi: 10.1186/s10194-025-01952-1.
3
An Integrative Migraine Polygenic Risk Score Is Associated with Age at Onset But Not Chronification.
综合偏头痛多基因风险评分与发病年龄相关,但与慢性化无关。
J Clin Med. 2024 Oct 29;13(21):6483. doi: 10.3390/jcm13216483.
4
Deep and unbiased proteomics, pathway enrichment analysis, and protein-protein interaction of biomarker signatures in migraine.偏头痛生物标志物特征的深度无偏蛋白质组学、通路富集分析及蛋白质-蛋白质相互作用
Ther Adv Chronic Dis. 2024 Sep 18;15:20406223241274302. doi: 10.1177/20406223241274302. eCollection 2024.
5
Prognostic subgroups of chronic pain patients using latent variable mixture modeling within a supervised machine learning framework.基于有监督机器学习框架的潜变量混合建模对慢性疼痛患者的预后亚组进行分析。
Sci Rep. 2024 May 31;14(1):12543. doi: 10.1038/s41598-024-62542-w.
6
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine.偏头痛对功能的影响:两项偏头痛患者生活质量定性研究的结果。
Headache. 2024 Feb;64(2):156-171. doi: 10.1111/head.14664. Epub 2024 Jan 18.
7
Risk factors for migraine disease progression: a narrative review for a patient-centered approach.偏头痛疾病进展的风险因素:以患者为中心的方法进行叙述性综述。
J Neurol. 2023 Dec;270(12):5692-5710. doi: 10.1007/s00415-023-11880-2. Epub 2023 Aug 24.
8
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.依帕司他联合甲钴胺治疗糖尿病周围神经病变的疗效观察 目的 观察依帕司他联合甲钴胺治疗糖尿病周围神经病变的临床疗效。 方法 将 100 例糖尿病周围神经病变患者随机分为两组,每组 50 例。两组患者均给予糖尿病基础治疗,对照组在基础治疗上加用甲钴胺 500 μg 静脉滴注,1 次/d;观察组在对照组治疗基础上加用依帕司他 50 mg,3 次/d。两组疗程均为 4 周。观察两组患者治疗前后的临床疗效、多伦多临床评分系统(TCSS)评分、神经传导速度(NCV)的变化。 结果 观察组总有效率为 92.0%,对照组为 76.0%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者的 TCSS 评分均较治疗前降低(P<0.05),且观察组 TCSS 评分低于对照组(P<0.05)。治疗后,两组患者的正中神经、腓总神经的运动神经传导速度(MCV)和感觉神经传导速度(SCV)均较治疗前升高(P<0.05),且观察组的 MCV 和 SCV 高于对照组(P<0.05)。 结论 依帕司他联合甲钴胺治疗糖尿病周围神经病变可有效改善患者的临床症状和神经传导速度,提高临床疗效。 结论:依帕司他联合甲钴胺治疗糖尿病周围神经病变可有效改善患者的临床症状和神经传导速度,提高临床疗效。
BMC Neurol. 2022 Oct 25;22(1):394. doi: 10.1186/s12883-022-02914-9.
9
Neurobiology of migraine progression.偏头痛进展的神经生物学
Neurobiol Pain. 2022 Jun 9;12:100094. doi: 10.1016/j.ynpai.2022.100094. eCollection 2022 Aug-Dec.
10
A population-health approach to characterizing migraine by comorbidity: Results from the Mindfulness and Migraine Cohort Study.采用人群健康方法通过合并症对偏头痛进行特征描述:正念与偏头痛队列研究的结果。
Cephalalgia. 2022 Oct;42(11-12):1255-1264. doi: 10.1177/03331024221104180. Epub 2022 May 31.